RD

SAP Knows: You Spend Money to Make Money

SAP showed healthy revenue growth in its recently announced first quarter earnings, but operating profits increased by far less. Why? Because the company is putting more money into operating expenses and R&D, which sets it up for bigger profits in the longer term.

Pfizer Sells Capsugel: Will More Asset Sales Follow?

On Monday, Pfizer announced it would sell its Capsugel business to private-equity firm KKR for $2.375 billion. If the hints the drugmaker has been giving lately are true, the move could be the start of two years of major asset sales. Here's what's ahead for the world's biggest pharmaceutical company.

Google's Future: Can Larry Page Make It a Winner Again?

Google has been dead money for the last year -- up just 3% vs. 12.6% for the S&P 500. The Internet giant's biggest problem is its inability to diversify its revenue sources. Author Peter Cohan pulls out his Innovation Quotient to suggest how new CEO Larry Page might correct that.

Pfizer Joins Other Pharmas in Giving a Cautious Outlook

Pfizer reported fourth-quarter earnings on Tuesday that nearly quadrupled from a year ago as revenue rose 6%. But it also lowered its sales guidance for 2012, due to some of its bestselling drugs going off patent. What's ahead for the world's biggest drugmaker:

New Management Guide Also Offers Value to Investors

Prestigious management consulting firm McKinsey & Co. just published 'Value: The Four Cornerstones of Corporate Finance,' a guide to help executives create shareholder value. Lead author Tim Koller shares his thoughts with DailyFinance about how the book might also help investors profit.

General Electric to Invest $2 Billion in China

General Electric, the global conglomerate whose businesses include consumer and business financing, power generation, household appliances, aircraft engines, medical imaging and media content, said it plans to invest more than $2 billion in China through 2012 in research and development, technology and financial services partnerships.

R&D Spending Fell in 2009 for the First Time in a Decade

Corporate America took a tightfisted approach to its future last year, leading to an overall 3.5% decline in research and development spending at major industry titans, the first such drop in over a decade, according to a Booz & Co. survey cited by The Wall Street Journal.

Sanofi-Aventis Inks 10-Year R&D Deal with Covance

French pharmaceutical company Sanofi-Aventis announced a 10-year agreement with Covance on Thursday under which the Princeton, N.J.-based contract research firm will provide it with drug development services. Sanofi-Aventis will pay Covance between $1.2 billion to $2.2 billion.